세계의 동물용 항균 및 항생제 시장 규모 : 제품별, 동물 유형별, 딜리버리 모드별, 지역별(2024-2031년)

Animal Antibacterial And Antibiotics Market Valuation - 2024-2031

Growing demand for leather and animal products for consumption is satisfactory with an increase in the population of healthy animals. Thus, the demand for animal products such as meat, milk, skin, and others is projected to offer immense growth prospects to the Animal Antibacterial And Antibiotics Market. In addition to this, the high prevalence of diseases among animals is another factor enabling the market. Animal Antibacterial And Antibiotics Market surpassed a revenue of USD 6.95 Billion in 2023 and continue growing to reach a valuation of aroundUSD 11.75 Billion by 2031.

The global population is growing, leading to an upsurge in demand for animal-derived protein sources like meat, poultry, eggs, and dairy products. This spurring demand necessitates an increase in animal populations through poultry practices, resulting in a higher prevalence of infections and a greater need for antibiotics for treatment and prevention. Thus, the current market is projected to grow substantially at aCAGR of approximately 6.10% from 2024 to 2031.

Animal Antibacterial And Antibiotics Market: Definition/ Overview

Animal antibacterial and antibiotics are treatments designed to treat bacterial illnesses, which are in the prophylaxis and metaphylaxis stage, in cattle, companion animals, and poultry. This form of treatment helps preserve animal health, prevent disease outbreaks, and ensure food safety by reducing bacterial infections in food-producing animals. It is present in a variety of forms, including oral pills, injectables, topical solutions, and feed additives. The government authorities control their manufacturing and commercialization to assure their safety, effectiveness, and correct usage in veterinary care.

Despite its effective benefits, it is discouraged and often banned in the majority of the regions due to concerns about antimicrobial resistance. However, the use of antibacterials for growth promotion still exists in some parts of the world. Growing awareness about antimicrobial resistance necessitates a shift towards responsible use practices, emphasizing only using antibiotics when prescribed by a veterinarian, completing the full course of treatment, and exploring alternative preventive measures. Also, evolving regulations worldwide aim to inhibit the overuse and misuse of antimicrobials in animals. This will likely influence market dynamics and encourage the adoption of responsible use practices.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Encouraging the Adoption of Animal Antibacterial And Antibiotics Market?

Growing population growth and income levels is bolstering the demand for animal protein, including meat, milk, and eggs. Therefore, there is a greater need to maintain the health and productivity of livestock and poultry to prevent and treat bacterial infections or zoonotic diseases using antibiotics.

As the animals are highly susceptible to various bacterial infections that can seriously affect their health and productivity, there is need for need for implementing intensive animal farming practices. Thus, the animal husbandry sector is majorly focusing on lowering overcrowding and other environmental stress to minimize risks of disease outbreaks in livestock and poultry.

Additionally, the use of antibacterial drugs and antibiotics is increasing to reduce mortality and economic losses of farmers, opening new doors of opportunities for the market. The rise in awareness among consumers regulators and industry stakeholders about animal welfare emphasizes ensuring the health and welfare of animals raised for food production so as to meet ethical standards and regulatory requirements.

Similarly, the use of these treatments for the well-being as well as promoting growth of the animals is concerning the regulatory bodies, thereby encouraging the manufacturers to develop eco-friendly drugs with minimal impact on human health. This regulatory support is anticipated to offer new avenues of growth to the Animal Antibacterial And Antibiotics Market.

Furthermore, increased pet ownership is surging investments in animal health, thereby boosting the potential potential use of antibiotics for treating infections in companion animals.

What are the Challenges Impacting the Growth of the Animal Antibacterial And Antibiotics Market?

Growing concerns regarding the spread of antimicrobial resistance (AMR) due to the overuse and misuse of antibiotics in animals is likely to result in bacteria developing resistance, thus, rendering existing antibiotics ineffective against these resistant strains. This poses a significant threat to animal and human health, as treating the resistant bacterial infections is difficult as well as expensive.

Changing government regulations globally against the use of prescribed veterinary drugs is creating challenges for global companies and hindering responsible use practices in some regions.

The availability of cheaper alternative drugs is projected to increase its usage, thereby contributing to the persistence of resistance issues associated with older antibiotics.

Moreover, inadequate awareness and education among farmers, veterinarians, and pet owners regarding responsible antibiotic use will further hinder its adoption. Similarly, the limited availability of effective and readily available alternatives to antibiotics for animal health poses a huge challenge. While research and development efforts are underway for novel antimicrobials and alternative solutions like vaccines and bacteriophages, their widespread adoption is likely to take time.

Category-Wise Acumens

Which Delivery Mode helps in the Growth of the Animal Antibacterial And Antibiotics Market?

Oral administration is anticipated to hold a major in the market over the forecast period. The easy availability at affordable prices and convenience in the usage of oral drugs is projected to help the segment retain its top-notch position in the Animal Antibacterial And Antibiotics Market.

In addition to this, the option of mass medication in food-producing animals further enhances its use through feed and water additives.

Consequently, the choice of catering to different animal preferences and ease of administration in oral formulations, including powders, tablets, premixes, and medicated feed additives, further boosts the demand for these treatments in animal husbandry.

Will the Effectiveness of Tetracyclines Help Skyrocket the Sales of Animal Antibacterial and Antibiotics?

As per our analyst, the tetracyclines segment is projected to hold the largest market share globally. This dominance is primarily due to their broad-spectrum effectiveness and affordability.

Also, their well-established application in veterinary practices is another driving factor despite its increasing and long-lasting impact on the development of bacterial resistance.

Another widely used segment is penicillin, particularly owing to its effectiveness against specific bacterial infections in food-producing animals. However, its dominance might also be affected owing to the changing resistance patterns and also the evolving regulatory restrictions.

Country/Region-wise Acumens

Which region has most potential for growth of Animal Antibacterial And Antibiotics Market?

According to VMR analyst, The Asia-Pacific region's fast-increasing population and rising disposable incomes are driving up demand for animal protein, such as meat, dairy, and eggs. As a result, there is an increasing need to protect the health and production of livestock and poultry by using antibacterial and antibiotics to prevent and cure bacterial diseases.

Economic development in Asia-Pacific countries has resulted in increased intensive agricultural techniques and upgrading of livestock and poultry production systems. This tendency has raised the need for veterinary medications, such as antibacterial and antibiotics, to treat the health risks linked with intensive animal agriculture. The Asia-Pacific area is vulnerable to a variety of infectious illnesses affecting cattle and poultry, such as respiratory diseases, gastrointestinal infections, and vector-borne diseases. Climate variability, urbanization, and globalization all contribute to the development of animal illnesses, resulting in a high need for antibacterial and antibiotics for disease prevention and treatment.

Many nations in the Asia-Pacific area are launching measures to improve animal health and welfare, raise food safety requirements, and promote sustainable agriculture methods. This includes expenditures in veterinary infrastructure, R&D, and regulatory frameworks to guarantee that antibacterial and antibiotics are used responsibly in animal husbandry.

Which Region Dominates in Animal Antibacterial And Antibiotics Market?

North America has a well-established veterinary health infrastructure, including veterinary clinics, hospitals, and diagnostic laboratories equipped with advanced diagnostic and treatment equipment. This infrastructure supports the diagnosis, treatment, and prevention of bacterial infections in animals, increasing demand for antibacterial and antibiotics. For instance,

the World Health Organization

reports that animal origins account for 70% of newly discovered human diseases. Therefore, Ceva has a responsibility to stop these zoonotic illnesses as a veterinarian company. To present, more than fifty vaccinations have been developed to protect against 19 major zoonoses. Furthermore, more than 50% of Ceva's product line consists of vaccinations and other treatments for animal care.

North America has a large and diverse livestock and poultry industry, including beef, dairy cows, swine, poultry, and aquaculture. Operations Intensive agricultural practices in this region create a significant demand for antibacterial agents and antibiotics to maintain the health and productivity of animals raised for food production. North American regulatory agencies such as the US Food and Drug Administration (FDA) and the Canadian Food Agency. (CFIA) has strict standards and regulations regarding the approval, distribution, and use of veterinary drugs, including antibacterial drugs and antibiotics. Compliance with the law ensures the safety, effectiveness, and quality of veterinary medicines in the region.

North American consumers are very aware and concerned about food safety, animal welfare and the use of antibiotics in livestock production. As a result, demand for animal products from animals raised without antibiotics is increasing, which encourages the adoption of alternative therapies and consumer preferences for veterinary medicines, enabling the region to hold a dominant position in the market.

Competitive Landscape

The competitive landscape in the Animal Antibacterial And Antibiotics Market is dynamic and evolving, driven by changing customer preferences and market dynamics. Providers continue to innovate and differentiate their offerings to stay competitive and capture market share in this rapidly growing industry.

Some of the prominent players operating in the Animal Antibacterial And Antibiotics Market include:

Ashish Life Science, Merck Animal Health, Ayurvet, H. Boehringer Sohn AG & Co. KG., Ceva Sante Animale, Merial, Biogenesis Bago, Bayer HealthCare, Elanco, Endovac Animal Health., HIPRA, S.A., ECO Animal Health, HUVEPHARMA, Kyoritsuseiyaku Corporation, Dechra Pharmaceuticals, Neogen Corporation, Phibro Animal Health Corporation, UCBVET Animal Health and Welfare, Vetoquinol, Virbac, Zoetis.

Latest Developments

In February 2024, Elanco Animal Health Incorporated entered into an agreement to sell its aqua business to Merck Animal Health (NYSE:

MRK

) for around USD 1.3 Billion in cash, which is 7.4x the revenue of the Elanco aqua business estimated in 2023.

In July 2022, Boehringer Ingelheim, Evotec SE, and bioMerieux signed a joint venture agreement to develop the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).

In May 2022, Ceva Sante Animale acquired Artemis Technologies, Inc., the Canadian oral rabies vaccine manufacturer. This acquisition will prove profitable as Ceva would be gaining control over the commercialization of ONRAB(R), a rabies glycoprotein recombinant oral vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Tetracyclines
• 5.3 Penicillins
• 5.4 Sulfonamides
• 5.5 Macrolides
• 5.6 Others

6 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY ANIMAL TYPE

• 6.1 Overview
• 6.2 Companion Animals
• 6.3 Food-Producing Animals

7 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY DELIVERY MODE

• 7.1 Overview
• 7.2 Oral Powder
• 7.3 Solutions Injections
• 7.4 Premix

8 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Zoetis
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Merck Animal Health
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Merial
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Elanco
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bayer HealthCare
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Biogenesis Bago
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 HUVEPHARMA
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ceva Sante Animale
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Dechra Pharmaceuticals
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 ECO Animal Health
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research